Van ECK Associates Corp boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,078,208 shares of the biopharmaceutical company’s stock after purchasing an additional 50,893 shares during the period. Van ECK Associates Corp’s holdings in Gilead Sciences were worth $67,442,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. S&CO Inc. lifted its position in shares of Gilead Sciences by 5.5% in the 4th quarter. S&CO Inc. now owns 6,325 shares of the biopharmaceutical company’s stock valued at $396,000 after acquiring an additional 330 shares in the last quarter. Addenda Capital Inc. lifted its position in shares of Gilead Sciences by 2.3% in the 4th quarter. Addenda Capital Inc. now owns 59,731 shares of the biopharmaceutical company’s stock valued at $3,735,000 after acquiring an additional 1,362 shares in the last quarter. IMA Wealth Inc. lifted its position in shares of Gilead Sciences by 31.6% in the 4th quarter. IMA Wealth Inc. now owns 7,121 shares of the biopharmaceutical company’s stock valued at $445,000 after acquiring an additional 1,710 shares in the last quarter. Clear Perspective Advisors LLC lifted its position in shares of Gilead Sciences by 3.6% in the 4th quarter. Clear Perspective Advisors LLC now owns 8,680 shares of the biopharmaceutical company’s stock valued at $543,000 after acquiring an additional 300 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Gilead Sciences by 199,789.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock valued at $2,420,587,000 after acquiring an additional 31,335,030 shares in the last quarter. Institutional investors and hedge funds own 78.23% of the company’s stock.

In other Gilead Sciences news, Director Gayle E. Wilson sold 19,068 shares of the stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $67.08, for a total value of $1,279,081.44. Following the completion of the sale, the director now owns 143,567 shares in the company, valued at approximately $9,630,474.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.16% of the stock is owned by corporate insiders.

Several equities research analysts recently commented on GILD shares. BidaskClub downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, November 21st. ValuEngine downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, November 21st. Guggenheim started coverage on shares of Gilead Sciences in a research report on Monday, December 17th. They issued a “buy” rating and a $86.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $92.00 price target on shares of Gilead Sciences in a research report on Wednesday, December 19th. Finally, Morgan Stanley upped their price target on shares of Gilead Sciences from $85.00 to $86.00 and gave the company an “equal weight” rating in a research report on Wednesday, December 19th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $82.29.

GILD stock opened at $65.63 on Friday. Gilead Sciences, Inc. has a 12-month low of $60.32 and a 12-month high of $80.90. The company has a debt-to-equity ratio of 1.19, a current ratio of 3.38 and a quick ratio of 3.29. The company has a market capitalization of $82.69 billion, a price-to-earnings ratio of 10.67, a P/E/G ratio of 4.08 and a beta of 1.16.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.70 by ($0.26). Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same quarter in the previous year, the company earned $1.78 EPS. The firm’s quarterly revenue was down 2.6% compared to the same quarter last year. On average, research analysts expect that Gilead Sciences, Inc. will post 6.23 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 28th. Shareholders of record on Friday, March 15th will be given a $0.63 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.57. The ex-dividend date is Thursday, March 14th. This represents a $2.52 dividend on an annualized basis and a yield of 3.84%. Gilead Sciences’s dividend payout ratio is presently 37.07%.

COPYRIGHT VIOLATION WARNING: “Van ECK Associates Corp Acquires 50,893 Shares of Gilead Sciences, Inc. (GILD)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/van-eck-associates-corp-acquires-50893-shares-of-gilead-sciences-inc-gild/2897122.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Article: What are Closed-End Mutual Funds?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.